- Trials with a EudraCT protocol (28,960)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
28,960 result(s) found for: Informed Consent.
Displaying page 709 of 1,448.
| EudraCT Number: 2006-001937-17 | Sponsor Protocol Number: SP879 | Start Date*: 2006-08-22 | |||||||||||
| Sponsor Name:Schwarz Biosciences GmbH | |||||||||||||
| Full Title: A randomized, double-blind, placebo-controlled, parallel-group proof-of-concept trial to assess the efficacy, safety and tolerability of ascending doses of rotigotine nasal spray for the acute trea... | |||||||||||||
| Medical condition: idiopathic Restless Leg's Syndrome | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-000741-12 | Sponsor Protocol Number: HZA112776 | Start Date*: 2012-03-08 | |||||||||||
| Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
| Full Title: A Randomized, Double blind, Placebo controlled, Two-Way Crossover 7-day study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Dose Inhaled GW642444 25μg in ... | |||||||||||||
| Medical condition: Asthma | |||||||||||||
|
|||||||||||||
| Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: Outside EU/EEA | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2019-002414-40 | Sponsor Protocol Number: CXA-10-2302 | Start Date*: 2019-12-17 | ||||||||||||||||
| Sponsor Name:Complexa Inc. | ||||||||||||||||||
| Full Title: A Phase 2, Multi-Center, Open-Label Study to Evaluate Long-term Safety and Efficacy of CXA-10 in Subjects with Pulmonary Arterial Hypertension on Stable Background Therapy: Extension to Study CXA-1... | ||||||||||||||||||
| Medical condition: Pulmonary Arterial Hypertension (PAH). | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: GB (Prematurely Ended) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2008-000991-26 | Sponsor Protocol Number: SUN-PDT1 | Start Date*: 2008-04-15 | |||||||||||
| Sponsor Name:Department of Dermatology, Bispebjerg Hospital | |||||||||||||
| Full Title: A RANDOMIZED, MULTICENTER STUDY OF DAYLIGHT MEDIATED PHOTODYNAMIC THERAPY WITH METVIX® CREAM 160 mg/g IN PATIENTS WITH MULTIPLE ACTINIC KERATOSIS ON THE FACE AND SCALP | |||||||||||||
| Medical condition: Actinic keratoses | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Completed) SE (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2013-002467-26 | Sponsor Protocol Number: 480-SFA2013-001 | Start Date*: 2013-08-30 |
| Sponsor Name:480 Biomedical, Inc. | ||
| Full Title: The SPRINT trial: An Evaluation of the 480 Biomedical STANZA™ Drug-Eluting Resorbable Scaffold (DRS) System v1.2 in the Treatment of de novo SFA Lesions | ||
| Medical condition: An evaluation of the safety and performance of the STANZA DRS v1.2 system for the treatment of patients with obstructive superficial femoral artery disease. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: AT (Prematurely Ended) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2014-001218-24 | Sponsor Protocol Number: TDL-CS-001 | Start Date*: 2014-06-05 | |||||||||||
| Sponsor Name:Trichocare Diagnostics Ltd | |||||||||||||
| Full Title: An open label, intra-subject, controlled multi-centre study to assess the concordance (specificity and sensitivity) between Colourstart® Test 73 mcg Cutaneous Patch and Finn Chamber in the detectio... | |||||||||||||
| Medical condition: Para-Phenylenediamine allergy | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2010-019035-35 | Sponsor Protocol Number: A0081194 | Start Date*: 2011-02-21 | |||||||||||
| Sponsor Name:Pfizer Inc. | |||||||||||||
| Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER TRIAL OF PREGABALIN CONTROLLED RELEASE FORMULATION AS ADJUNCTIVE THERAPY IN ADULTS WITH PARTIAL ONSET SEIZURES - PROTOCO... | |||||||||||||
| Medical condition: Adjunctive (add on) therapy for adult subjects with partial onset seizures with or without secondary generalization. | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: CZ (Completed) HU (Completed) DE (Completed) BG (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2006-006073-24 | Sponsor Protocol Number: CCR2983 | Start Date*: 2008-05-22 | ||||||||||||||||
| Sponsor Name:Royal Marsden Hospital | ||||||||||||||||||
| Full Title: CINATRA: Chromosomal Instability and Anti-Tubulin Response Assessment: A Phase II Study of Epothilone B in Metastatic Colon Carcinoma in patients with Microsatellite Instability or Chromosomal Inst... | ||||||||||||||||||
| Medical condition: Metastatic or locally recurrent colorectal cancer in genetically unselected patients, followed by recruitment of patients selected for microsatellite positive tumours | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: GB (Prematurely Ended) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2010-020300-29 | Sponsor Protocol Number: A0081231 | Start Date*: 2010-11-03 | |||||||||||
| Sponsor Name:Pfizer Inc. | |||||||||||||
| Full Title: A 6-MONTH, OPEN-LABEL, SAFETY TRIAL OF PREGABALIN IN ADOLESCENT PATIENTS WITH FIBROMYALGIA | |||||||||||||
| Medical condition: Adolescent fibromyalgia | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: CZ (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2008-004695-49 | Sponsor Protocol Number: 08-01 / Ter-C | Start Date*: 2009-01-13 | |||||||||||
| Sponsor Name:Dermapharm AG | |||||||||||||
| Full Title: Doppelblinde, randomisierte klinische Studie zum Vergleich der Wirksamkeit und Verträglichkeit von Terbinafin Creme 1% vs. Lamisil® Creme vs. Grundlage bei Patienten mit Tinea pedis | |||||||||||||
| Medical condition: Tinea pedis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2006-006881-40 | Sponsor Protocol Number: AURA-6202-005 | Start Date*: 2007-01-31 | |||||||||||
| Sponsor Name:NERVIANO MEDICAL SCIENCES | |||||||||||||
| Full Title: A pilot Phase II study of PHA-739358 in patients with Chronic Myeloid Leukemia relapsing on Gleevec or c-ABL therapy | |||||||||||||
| Medical condition: Treatment of Chronic Myeloid Leukemia | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2007-000790-36 | Sponsor Protocol Number: A6281282 | Start Date*: 2008-01-08 | |||||||||||
| Sponsor Name:Pfizer Pharma GmbH | |||||||||||||
| Full Title: Prospective, randomized, double blind placebo-controlled trial on the efficacy of growth hormone replacement therapy in adult patients with isolated growth hormone deficiency (PRO ISO-GHD Study) | |||||||||||||
| Medical condition: Isolated Adult Growth Hormone Deficiency | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2018-003620-37 | Sponsor Protocol Number: STH19580 | Start Date*: 2019-10-31 | |||||||||||
| Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust | |||||||||||||
| Full Title: NEPTUNE: Enhancement of immuNothEraPy combining avelumab and repeaT doses of radiUm-223 in ER+ve, HER2-ve metastatic breast caNcEr. | |||||||||||||
| Medical condition: ER+ve HER-ve breast cancer with bone metastases | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2016-000998-20 | Sponsor Protocol Number: DRO/IV-2016-ART-02 | Start Date*: 2016-06-08 |
| Sponsor Name:BIOIBÉRICA S.A | ||
| Full Title: Double-Blind, Randomised, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of the Combination of Chondroitin Sulphate and Glucosamine Hydrochloride in Patients with Hand Osteoa... | ||
| Medical condition: symptomatic hand osteoarthritis | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: ES (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2018-000918-38 | Sponsor Protocol Number: C0311002 | Start Date*: 2019-05-16 | |||||||||||
| Sponsor Name:Pfizer Inc. | |||||||||||||
| Full Title: A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL, CROSSOVER STUDY ASSESSING SUBJECT PERCEPTION OF TREATMENT BURDEN WITH USE OF WEEKLY GROWTH HORMONE (SOMATROGON) VERSUS DAILY GROWTH HORMONE (GENOTROP... | |||||||||||||
| Medical condition: Growth Hormone Deficiency in Children | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) SK (Completed) CZ (Completed) BG (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-000863-17 | Sponsor Protocol Number: SHP633-303 | Start Date*: 2017-03-28 | |||||||||||
| Sponsor Name:Shire Human Genetic Therapies, Inc. | |||||||||||||
| Full Title: A Retrospective and Prospective, Open-label, Long-term Safety and Efficacy Study of Teduglutide in Pediatric Subjects with Short Bowel Syndrome Who Completed TED-C13-003 Original PIP P/238/2010 | |||||||||||||
| Medical condition: short bowel syndrome | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2018-003852-19 | Sponsor Protocol Number: DOAC | Start Date*: 2019-03-29 | |||||||||||
| Sponsor Name:King's College London [...] | |||||||||||||
| Full Title: An Open Label, Non-Randomised, Phase IV Clinical Trial to Determine the Transfer of Apixaban and Rivaroxaban in Breast Milk Following Oral Administration | |||||||||||||
| Medical condition: healthy volunteers (Venous Thromboembolism) | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||
| Trial protocol: GB (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2021-001768-95 | Sponsor Protocol Number: 0420-20 | Start Date*: 2021-03-31 | |||||||||||
| Sponsor Name:Intas Pharmaceuticals Ltd. | |||||||||||||
| Full Title: AN OPEN LABEL, BALANCED, RANDOMIZED, TWO-TREATMENT, TWO-PERIOD, TWOSEQUENCE, SINGLE ORAL DOSE, CROSSOVER, COMPARATIVE BIOAVAILABILITY STUDY OF IMATINIB ORAL SOLUTION 800 MG/10 ML (AT A DOSE OF 05 M... | |||||||||||||
| Medical condition: Healthy volunteers (Chronic Myeloid Leukaemia, Acute Lymphoblastic Leukaemia, Myelodysplastic/myeloproliferative diseases, advanced hypereosinophilic syndrome and/or chronic eosinophilic leukaemia) | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: Outside EU/EEA | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2005-001484-64 | Sponsor Protocol Number: IBCSG 27-02/BIG 1-02/GEICAM 2002/04 | Start Date*: 2006-04-06 | |||||||||||
| Sponsor Name:International Breast Cancer Study Group (IBCSG) | |||||||||||||
| Full Title: Chemotherapy for Radically Resected Loco-regional Relapse A randomized clinical trial of adjuvant chemotherapy for radically resected loco-regional relapse of breast cancer Chemotherapy vs. Observa... | |||||||||||||
| Medical condition: Patients with radically treated isolated local and/or regional recurrence of invasive breast cancer after mastectomy or breast-conserving surgery. | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||
| Trial protocol: BE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2006-006481-42 | Sponsor Protocol Number: 769 | Start Date*: 2007-01-16 | |||||||||||
| Sponsor Name:Orbus International BV | |||||||||||||
| Full Title: HEALING IIB - Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth A Clinical, Multi-center, Prospective, non-Randomized Study | |||||||||||||
| Medical condition: Patients with ischemic hear disease with up to two de novo native coronary artery lesions. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.